Timing-specific Debridement, Antibiotics, and Implant Retention and 2-Stage Revision for Megaprosthesis-Related Infection: Optimizing the Window Period for Improved Outcomes

针对巨型假体相关感染的时机特异性清创、抗生素治疗、假体保留和两阶段翻修:优化治疗窗口期以改善治疗效果

阅读:2

Abstract

BACKGROUND: This study aimed to evaluate the outcomes of debridement, antibiotics, and implant retention (DAIR) procedures and 2-stage revision surgeries in patients with periprosthetic joint infection following megaprosthesis, including treatment failure; the patient-reported outcomes; and to determine the survival rates of the revised megaprosthesis. METHODS: A retrospective study of 30 patients diagnosed with periprosthetic joint infection following megaprosthesis between 2018 and 2023, with minimum 1-year follow-up. Patients with previous unsuccessful debridement in other institutions were excluded. Patients presenting within 4 weeks of megaprosthesis implantation underwent the DAIR procedure, while those presenting after this window were taken for a 2-stage revision surgery. The primary outcome was treatment failure, defined as persistent wound complication or the need for subsequent surgical intervention. The secondary outcomes included patient-reported outcomes, assessed with the Oxford Hip Score and Oxford Knee Score, and the survival rates of the revised megaprosthesis. RESULTS: The mean follow-up duration for all patients was 38 ± 12.6 months. Improvement was found for Oxford Hip Score and Oxford Knee Score with mean 34.22 ± 9.2 and 32.40 ± 8.1, respectively, at the 1-year follow-up. DAIR achieved an 81% success rate (13 out of 16) and 2-stage exchange had a 71.4% success rate (10 out of 14). CONCLUSIONS: Both DAIR and 2-stage exchange procedures yielded favorable functional outcomes with satisfactory 2-year survival function. Careful patient selection and indication management are crucial for optimal results. LEVEL OF EVIDENCE: Level IV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。